MPO, HDL Dysfunction and Cardiovascular Disease
MPO、HDL 功能障碍与心血管疾病
基本信息
- 批准号:9265931
- 负责人:
- 金额:$ 71.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-07-01 至 2019-04-30
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAffectAngiographyAnimal ModelAnimal Testing AlternativesAnimalsAntiatherogenicApolipoprotein A-IArterial Fatty StreakAtherosclerosisBiological MarkersBiologyCRISPR/Cas technologyCardiac Catheterization ProceduresCardiovascular DiseasesCharacteristicsCholesterolCoronaryCoronary heart diseaseDataDevelopmentDiagnosticDietDiseaseDrug TargetingEnzymesEventFailureFramingham Heart StudyFunctional disorderHigh Density LipoproteinsHumanIndividualInflammatoryKnock-outKnowledgeLipidsLow-Density LipoproteinsMediator of activation proteinModelingMolecularMonitorMusMyocardial InfarctionMyocardial dysfunctionNicotinic AcidsOryctolagus cuniculusOxidative StressOxidesPathogenesisPatientsPeroxidasesPharmaceutical PreparationsPharmacologyProteinsProteomicsReportingRoleRuptureSourceStudy modelsSudden DeathTechnologyTherapeuticTimeTissuesWorkatherogenesisatheroprotectivebasebiomarker panelclinically relevantdiagnostic panelenzyme activityepidemiology studyexperimental studyheme ainhibitor/antagonistmacrophagenoveloxidationparticlepublic health relevanceresearch and developmenttooltorcetrapib
项目摘要
DESCRIPTION (provided by applicant): Oxidative stress is implicated in atherogenesis and plaque rupture-the major cause of myocardial infarction (MI) and sudden death. One of the well-characterized sources of oxidative stress is myeloperoxidase (MPO), a heme enzyme that co-localizes with macrophages in human atherosclerotic lesions. Epidemiology studies show that individuals possessing high MPO levels among sequential subjects undergoing diagnostic cardiac catheterization were 15- to 20-fold more likely to demonstrate abnormal coronary angiograms compared with subjects in the lowest quartile. Consistently, individuals with total or subtotal MPO deficiency appear less likely to have CVD development. Importantly, MPO selectively modifies apolipoprotein A-1 (ApoA-I), generating dysfunctional HDL. Here we hypothesize that inhibiting MPO is beneficial to the quality of HDL, which consequently exert atheroprotective effects on the patients. We propose experiments to determine whether MPO is an effective target for reducing atherosclerosis, and to define the roles of MPO on HDL functionality in atherogenesis. We have successfully generated MPO knockout (KO) rabbits using the CRISPR/Cas9 technology. These novel rabbit models will be employed in the present study. We expect establishing a meaningful animal model for the study of MPO biology, gaining novel knowledge, and facilitating the R&D of MPO based therapeutics and diagnostics. Specifically, we will 1) Determine whether MPO is an effective target for reducing atherosclerosis in rabbits; 2) Define the roles of MPO on HDL functionality in atherogenesis using novel rabbit models. It is well documented that mice are not appropriate for the study of MPO biology. Only trace amount of MPO can be detected in atherosclerotic tissues in mice, dwarf to that found in human counterpart. Moreover, mice deficient of MPO showed increased atherosclerosis, opposite to what is observed in humans. This project thus has a unique advantage in resolving such debate (i.e. MPO be atherogenic or anti-atherogenic) by using the novel MPO knockout rabbit models, a species that has been a classic model to study human lipid biology and CVD.
描述(由申请人提供):氧化应激与动脉粥样硬化和斑块破裂有关,这是心肌梗死(MI)和猝死的主要原因之一,氧化应激的一个明确来源是髓过氧化物酶(MPO),它是一种血红素酶,可导致心肌梗死(MI)和猝死。流行病学研究表明,在接受心脏诊断的连续受试者中,MPO 水平较高。与最低四分位数的受试者相比,导管插入术显示异常冠状动脉血管造影的可能性高出 15 至 20 倍。同样,MPO 完全或部分缺乏的个体似乎不太可能发生 CVD。重要的是,MPO 选择性地改变载脂蛋白 A-1。 ApoA-I),产生功能失调的 HDL。在这里,我们追求抑制 MPO 有利于 HDL 的质量,从而对患者产生动脉粥样硬化作用。确定 MPO 是否是减少动脉粥样硬化的有效靶点,并确定 MPO 在动脉粥样硬化形成中对 HDL 功能的作用,我们已使用 CRISPR/Cas9 技术成功生成了 MPO 敲除 (KO) 兔子,这些新型兔子模型将用于研究。我们期望建立一个有意义的动物模型来研究 MPO 生物学,获得新的知识,并促进基于 MPO 的治疗和诊断的研发。具体来说,我们将 1) 确定 MPO 是否是。减少兔子动脉粥样硬化的有效靶标;2) 使用新型兔子模型确定 MPO 对 HDL 功能的作用,有充分证据表明小鼠不适合研究 MPO 生物学,只能检测到痕量的 MPO。此外,缺乏 MPO 的小鼠表现出动脉粥样硬化增加,这与在人类中观察到的情况相反,因此该项目在解决这一问题方面具有独特的优势。通过使用新型 MPO 敲除兔模型(该物种已成为研究人类脂质生物学和 CVD 的经典模型),可以解决此类争论(即 MPO 是致动脉粥样硬化还是抗动脉粥样硬化)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YUQING Eugene CHEN其他文献
YUQING Eugene CHEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YUQING Eugene CHEN', 18)}}的其他基金
Browning of perivascular adipose tissue protects against thoracic aortic aneurysm
血管周围脂肪组织褐变可预防胸主动脉瘤
- 批准号:
10462357 - 财政年份:2022
- 资助金额:
$ 71.68万 - 项目类别:
Browning of perivascular adipose tissue protects against thoracic aortic aneurysm
血管周围脂肪组织褐变可预防胸主动脉瘤
- 批准号:
10580855 - 财政年份:2022
- 资助金额:
$ 71.68万 - 项目类别:
Development of gene editing based therapy for cardiovascular diseases
开发基于基因编辑的心血管疾病疗法
- 批准号:
10313701 - 财政年份:2021
- 资助金额:
$ 71.68万 - 项目类别:
Development of gene editing based therapy for cardiovascular diseases
开发基于基因编辑的心血管疾病疗法
- 批准号:
10441548 - 财政年份:2021
- 资助金额:
$ 71.68万 - 项目类别:
Development of gene editing based therapy for cardiovascular diseases
开发基于基因编辑的心血管疾病疗法
- 批准号:
10652321 - 财政年份:2021
- 资助金额:
$ 71.68万 - 项目类别:
Development of gene editing based therapy for cardiovascular diseases
开发基于基因编辑的心血管疾病疗法
- 批准号:
10441548 - 财政年份:2021
- 资助金额:
$ 71.68万 - 项目类别:
IDOL and dyslipidemia in cardiovascular diseases
IDOL 与心血管疾病中的血脂异常
- 批准号:
10221773 - 财政年份:2019
- 资助金额:
$ 71.68万 - 项目类别:
IDOL and dyslipidemia in cardiovascular diseases
IDOL 与心血管疾病中的血脂异常
- 批准号:
10451711 - 财政年份:2019
- 资助金额:
$ 71.68万 - 项目类别:
相似国自然基金
基于lncRNA NONHSAT042241/hnRNP D/β-catenin轴探讨雷公藤衍生物(LLDT-8)对类风湿关节炎滑膜成纤维细胞功能影响及机制研究
- 批准号:82304988
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
针刺手法和参数对针刺效应启动的影响及其机制
- 批准号:82305416
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
二仙汤影响肾上腺皮质-髓质激素分泌及调控下丘脑温度感受器以缓解“天癸竭”潮热的研究
- 批准号:82374307
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
固定翼海空跨域航行器出水稳定性与流体动力载荷影响机制
- 批准号:52371327
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
经济制裁对跨国企业海外研发网络建构的影响:基于被制裁企业的视角
- 批准号:72302155
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Intracellular RNA Nanoparticle Therapeutics to Treat Retinal Neovascularization
细胞内 RNA 纳米颗粒治疗视网膜新生血管
- 批准号:
10717749 - 财政年份:2023
- 资助金额:
$ 71.68万 - 项目类别:
Continuous Monitoring and Management of Vaginal Health via Multifunctional OCT/OCTA Endoscopy
通过多功能 OCT/OCTA 内窥镜持续监测和管理阴道健康
- 批准号:
10297772 - 财政年份:2021
- 资助金额:
$ 71.68万 - 项目类别:
Continuous Monitoring and Management of Vaginal Health via Multifunctional OCT/OCTA Endoscopy
通过多功能 OCT/OCTA 内窥镜持续监测和管理阴道健康
- 批准号:
10297772 - 财政年份:2021
- 资助金额:
$ 71.68万 - 项目类别:
Sex-Specific Patterns of Myocardial Ischemia During Mental and Conventional Stress
精神和常规应激期间心肌缺血的性别特异性模式
- 批准号:
9911804 - 财政年份:2020
- 资助金额:
$ 71.68万 - 项目类别: